Freedom of Information request 171-2021

Trust HQ
Edward Jenner Court
1010 Pioneer Avenue
Brockworth
Gloucester
GL3 4AW
Tel: 0300 421 8100
E-mail: freedomofinformation@ghc.nhs.uk Website: www.ghc.nhs.uk
Date: 20th July 2022
Sent via e-mail to:- Oliver Caswell request-875824-c5b091df@whatdotheyknow.com
————————-Oliver Caswell
Freedom of Information Request – Ref: FOI 171-2022
Thank you for your recent Freedom of Information request. Please find our response below:
The following questions with regards to patients treated in your trust are being asked for on behalf of Novartis.
1. In total, over the past 4 months, how many patients have been treated for the following diseases Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa.?
Our MSK Outpatient Services Physio/OT. provide assessment and advice on self-management, exercises, pacing, posture, etc; but, we do not have data about numbers of particular conditions as SystmOne does not currently code for conditions.
2. Of these five, how many of each received the following products:
– Adalimumab Humira.
– Adalimumab Biosimilar
– Etanercept Enbrel.
– Etanercept Biosimilar
– Infliximab Remicade.
– Infliximab biosimilar
– Golimumab Simponi.
– Tofacitinib Xeljanz.
– Ustekinumab Stelara.
– Vedolizumab Entyvio.
– Filgotinib Jyseleca.
– Abatacept Orencia.
– Baricitinib Olumiant.
– Certolizumab Pegol Cimzia.
– Rituximab MabThera.
– Rituximab Biosimilar
– Tocilizumab RoActemra.
– Sarilumab Kevzara.
– Apremilast Otezla.
– Secukinumab Cosentyx.
– Isekizumab Taltz.
– Guselkumab Tremfya.
– Brodalumab Kyntheum.
– Risankizumab Skyrizi.
– Tildrakizumab Ilumetri.
– Upadacitinib Rinvoq.
– Bimekizumab Bimzelx.
No patients in GHC, as all the medications listed would be from the Acute Trust.
2. Could you please provide the number of these patients that were treated within the gastro department still split by disease and treatment..
This trust doesn’t have a Gastro Dept.
4. Over the same time period, how many patients for each of the five diseases Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa. received the following treatments as their first ever biologic treatment?
– AxSPA
– PsA
– PsO
Same as Q2: No patients in GHC, as all the treatments listed would be from the Acute Trust
Should you have any queries in relation to our response in this letter, please do not hesitate to contact me. If you are unhappy with the response you have received in relation to your request and wish to ask us to review our response, you should write to: –
– Head of Legal Services / Associate Director of Corporate Governance Gloucestershire Health and Care NHS Foundation Trust
Edward Jenner Court
1010 Pioneer Avenue
Gloucester Business Park
Brockworth
GLOUCESTER GL3 4AW
——-
E-mail: —
If you are not content with the outcome of any review, you may apply directly to the Information Commissioner’s Office ICO. for further advice/guidance. Generally, the ICO will not consider your case unless you have exhausted your enquiries with the Trust which should include considering the use of the Trust’s formal complaints procedure. The ICO can be contacted at: The Information Commissioner’s Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.
Yours sincerely,
Freedom of Information Officer
On behalf of Gloucestershire Health & Care NHS Foundation Trust